Nanotechnology-mediated delivery of resveratrol as promising strategy to improve therapeutic efficacy in triple negative breast cancer (TNBC): progress and promises

References

• Mandapati A, Lukong KE. Triple negative breast cancer: approved treatment options and their mechanisms of action. J Cancer Res Clin Oncol. 2023;149(7):3701–19. doi: 10.1007/s00432-022-04189-6
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. doi: 10.1038/35021093
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Jovanović B, Chen XI, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. doi: 10.1371/journal.pone.0157368
   PubMed Web of Science ®Google Scholar
• Mitra S, Dash R. Natural products for the management and prevention of breast cancer. Evid Based Complementary Alter Med. 2018;2018:1–23. doi: 10.1155/2018/8324696
   Web of Science ®Google Scholar
• Israel BE, Tilghman SL, Parker‑Lemieux K, et al. Phytochemicals: Current strategies for treating breast cancer. Oncol Lett. 2018;15(5):7471–7478. doi: 10.3892/ol.2018.8304
   PubMed Web of Science ®Google Scholar
• Barkat MA, Ahmad J, Khan MA, et al. Insights into the targeting potential of thymoquinone for therapeutic intervention against triple-negative breast cancer. Curr Drug Targets. 2018;19(1):70–80. doi: 10.2174/1389450118666170612095959
   PubMed Web of Science ®Google Scholar
• Chalakur-Ramireddy NK, Pakala SB. Combined drug therapeutic strategies for the effective treatment of triple negative breast cancer. Bioscie Rep. 2018;38(1):BSR20171357. doi: 10.1042/BSR20171357
   PubMedGoogle Scholar
• Thakur KK, Bordoloi D, Kunnumakkara AB. Alarming burden of triple-negative breast cancer in India. Clin Breast Cancer. 2018;18(3):e393–9. doi: 10.1016/j.clbc.2017.07.013
   PubMed Web of Science ®Google Scholar
• Jitariu AA, Cîmpean AM, Ribatti D, et al. Triple negative breast cancer: the kiss of death. Oncotarget. 2017;8(28):46652. doi: 10.18632/oncotarget.16938
   PubMedGoogle Scholar
• Mahmoud R, Ordóñez-Morán P, Allegrucci C. Challenges for triple negative breast cancer treatment: Defeating heterogeneity and cancer stemness. Cancers (Basel). 2022;14(17):4280. doi: 10.3390/cancers14174280
   PubMed Web of Science ®Google Scholar
• Keshavarz G, Jalili C, Pazhouhi M, et al. Resveratrol effect on adipose-derived stem cells differentiation to chondrocyte in three-dimensional culture. Adv Pharm Bull. 2020;10(1):88. doi: 10.15171/apb.2020.011
   PubMed Web of Science ®Google Scholar
• Khazaei MR, Rashidi Z, Chobsaz F, et al. Inhibitory effect of resveratrol on the growth and angiogenesis of human endometrial tissue in an in vitro three-dimensional model of endometriosis. Reprod Biol. 2020;20(4):484–90. doi: 10.1016/j.repbio.2020.07.012
   PubMed Web of Science ®Google Scholar
• Bozorgi A, Khazaei S, Khademi A, et al. Natural and herbal compounds targeting breast cancer, a review based on cancer stem cells. Iran J Basic Med Sci. 2020;23(8):970. doi: 10.22038/ijbms.2020.43745.10270
   PubMed Web of Science ®Google Scholar
• Kim YN, Choe SR, Cho KH, et al. Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis. Exp Mol Med. 2017;49(2):e296–. doi: 10.1038/emm.2016.151
   PubMed Web of Science ®Google Scholar
• Ren B, Kwah MX, Liu C, et al. Resveratrol for cancer therapy: challenges and future perspectives. Cancer Lett. 2021;515:63–72. doi: 10.1016/j.canlet.2021.05.001
   PubMed Web of Science ®Google Scholar
• Davidov-Pardo G, McClements DJ. Resveratrol encapsulation: designing delivery systems to overcome solubility, stability and bioavailability issues. Trends Food Sci. 2014;38(2):88–103.
   Web of Science ®Google Scholar
• Orallo F. Comparative studies of the antioxidant effects of cis-and trans-resveratrol. Curr Med Chem. 2006;13(1):87–98. doi: 10.2174/092986706775197962
   PubMed Web of Science ®Google Scholar
• Santos AC, Veiga F, Ribeiro AJ. New delivery systems to improve the bioavailability of resveratrol. Expert Opin Drug Deliv. 2011;8(8):973–90. doi: 10.1517/17425247.2011.581655
   PubMed Web of Science ®Google Scholar
• Pangeni R, Sahni JK, Ali J, et al. Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv. 2014;11(8):1285–98. doi: 10.1517/17425247.2014.919253
   PubMed Web of Science ®Google Scholar
• Miller‐Kleinhenz JM, Bozeman EN, Yang L. Targeted nanoparticles for image-guided treatment of triple‐negative breast cancer: clinical significance and technological advances. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(6):797–816.
   PubMed Web of Science ®Google Scholar
• Choi H, Kim K. Theranostics for Triple-Negative breast cancer. Diagnostics. 2023;13(2):272.
   Web of Science ®Google Scholar
• Jain V, Kumar H, Anod HV, et al. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. J Control Release. 2020;326:628–47. doi: 10.1016/j.jconrel.2020.07.003
   PubMed Web of Science ®Google Scholar
• Chaudhuri A, Kumar DN, Dehari D, et al. Emergence of nanotechnology as a powerful cavalry against triple-negative breast cancer (TNBC). Pharmaceuticals. 2022;15(5):542. doi: 10.3390/ph15050542
   Web of Science ®Google Scholar
• Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493–506. doi: 10.1038/nrd2060
   PubMed Web of Science ®Google Scholar
• Thapa SB, Pandey RP, Park YI, et al. Biotechnological advances in resveratrol production and its chemical diversity. Molecules. 2019;24(14):2571. doi: 10.3390/molecules24142571
   PubMed Web of Science ®Google Scholar
• Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract. 2016;25(Suppl. 2):41–59. doi: 10.1159/000443404
   PubMedGoogle Scholar
• Shen J, Zhou Q, Li P, et al. Update on phytochemistry and pharmacology of naturally occurring resveratrol oligomers. Molecules. 2017;22(12):2050. doi: 10.3390/molecules22122050
   PubMed Web of Science ®Google Scholar
• Sparvoli F, Martin C, Scienza A, et al. Cloning and molecular analysis of structural genes involved in flavonoid and stilbene biosynthesis in grape (Vitis vinifera L.). Plant Mol Biol. 1994;24(5):743–55. doi: 10.1007/BF00029856
   PubMed Web of Science ®Google Scholar
• Pannu N, Bhatnagar A. Resveratrol: from enhanced biosynthesis and bioavailability to multitargeting chronic diseases. Biomed Pharmacother. 2019;109:2237–2251. doi: 10.1016/j.biopha.2018.11.075
   PubMed Web of Science ®Google Scholar
• Jeong YJ, Woo SG, An CH, et al. Metabolic engineering for resveratrol derivative biosynthesis in Escherichia coli. Mole Cells. 2015;38(4):318. doi: 10.14348/molcells.2015.2188
   Google Scholar
• Lizard G, Latruffe N, Vervandier-Fasseur D. Aza-and azo-stilbenes: bio-isosteric analogs of resveratrol. Molecules. 2020;25(3):605. doi: 10.3390/molecules25030605
   PubMed Web of Science ®Google Scholar
• Leischner C, Burkard M, Michel A, et al. Comparative analysis of the antitumor activity of cis-and trans-resveratrol in human cancer cells with different p53 status. Molecules. 2021;26(18):5586. doi: 10.3390/molecules26185586
   PubMed Web of Science ®Google Scholar
• Cai YJ, Wei QY, Fang JG, et al. The 3, 4-dihydroxyl groups are important for trans-resveratrol analogs to exhibit enhanced antioxidant and apoptotic activities. Anticancer Res. 2004;24(2B):999–1002.
   PubMed Web of Science ®Google Scholar
• Ovesna Z, Horvathova-Kozics K. Structure-activity relationship of trans-resveratrol and its analogues. Neoplasma. 2005;52(6):450.
   PubMed Web of Science ®Google Scholar
• Stojanović S, Sprinz H, Brede O. Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Arch Biochem Biophys. 2001;391(1):79–89. doi: 10.1006/abbi.2001.2388
   PubMed Web of Science ®Google Scholar
• Stivala LA, Savio M, Carafoli F, et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem. 2001;276(25):22586–94. doi: 10.1074/jbc.M101846200
   PubMed Web of Science ®Google Scholar
• Chillemi R, Sciuto S, Spatafora C, et al. Anti-tumor properties of stilbene-based resveratrol analogues: recent results. Nat Prod Commun. 2007;2(4):1934578X0700200419. doi: 10.1177/1934578X0700200419
   Web of Science ®Google Scholar
• Lion CJ, Matthews CS, Stevens MF, et al. Synthesis, antitumor evaluation, and apoptosis-inducing activity of hydroxylated (E)-stilbenes. J Med Chem. 2005;48(4):1292–1295. doi: 10.1021/jm049238e
   PubMed Web of Science ®Google Scholar
• Avtanski D, Poretsky L. Phyto-polyphenols as potential inhibitors of breast cancer metastasis. Mol Med. 2018;24(1):1–7. doi: 10.1186/s10020-018-0032-7
   PubMedGoogle Scholar
• Yeh SJ, Hsu BJ, Chen BS. Systems medicine design for triple-negative breast cancer and non-triple-negative breast cancer based on systems identification and carcinogenic mechanisms. Int J Mol Sci. 2021;22(6):3083. doi: 10.3390/ijms22063083
   PubMed Web of Science ®Google Scholar
• Mohammadhosseinpour S, Ho LC, Fang L, et al. Arachidin-1, a prenylated stilbenoid from peanut, induces apoptosis in triple-negative breast cancer cells. Int Mol Sci. 2022;23(3):1139. doi: 10.3390/ijms23031139
   PubMed Web of Science ®Google Scholar
• Saraiva D, Cabral MG, Jacinto A, et al. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open. 2017;2(4):e000208. doi: 10.1136/esmoopen-2017-000208
   PubMed Web of Science ®Google Scholar
• Kala R, Tollefsbol TO, Castresana JS. A novel combinatorial epigenetic therapy using resveratrol and pterostilbene for restoring estrogen receptor-α (ERα) expression in ERα-negative breast cancer cells. PloS One. 2016;11(5):e0155057. doi: 10.1371/journal.pone.0155057
   PubMed Web of Science ®Google Scholar
• Aguirre L, Fernández-Quintela A, Arias N, et al. Resveratrol: anti-obesity mechanisms of action. Molecules. 2014;19(11):18632–55. doi: 10.3390/molecules191118632
   PubMed Web of Science ®Google Scholar
• Haque I, Subramanian A, Huang CH, et al. The role of compounds derived from natural supplement as anticancer agents in renal cell carcinoma: a review. Int J Mol Sci. 2017;19(1):107. doi: 10.3390/ijms19010107
   PubMed Web of Science ®Google Scholar
• Abdal Dayem A, Choi HY, Yang GM, et al. The anti-cancer effect of polyphenols against breast cancer and cancer stem cells: molecular mechanisms. Nutrients. 2016;8(9):581. doi: 10.3390/nu8090581
   PubMed Web of Science ®Google Scholar
• Dandawate PR, Subramaniam D, Jensen RA, et al. Targeting cancer stem cells and signaling pathways by phytochemicals: novel approach for breast cancer therapy. Semin Cancer Biol. 2016;40:192–208. doi: 10.1016/j.semcancer.2016.09.001
   PubMed Web of Science ®Google Scholar
• Carter LG, D’Orazio JA, Pearson KJ. Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer. 2014;21(3):R209. doi: 10.1530/ERC-13-0171
   PubMed Web of Science ®Google Scholar
• Liu Q, Kim C, Jo YH, et al. Synthesis and biological evaluation of resveratrol derivatives as melanogenesis inhibitors. Molecules. 2015;20(9):16933–45. doi: 10.3390/molecules200916933
   PubMed Web of Science ®Google Scholar
• Yang L, Yao C, Lv X, et al. Synergistic anticancer activity of 3, 3’-diindolylmethane and genistein in MCF-7 and MDA-MB-231 human breast cancer cells. Oncol Lett. 2019;17(5):4607–4613. doi: 10.3892/ol.2019.10138
   PubMedGoogle Scholar
• Zhang Y, Li M, Li X, et al. Resveratrol induces autophagic apoptosis via the lysosomal cathepsin D pathway in human drug‑resistant K562/ADM leukemia cells. Exp Ther Med. 2019;18(1):475–488. doi: 10.3892/etm.2018.5742
   PubMedGoogle Scholar
• Li Q, Wang Z, Zhang Y, et al. Resveratrol inhibits the wnt signaling pathway and inhibits adipocyte differentiation via inhibiting P300 and Catenin. Mol Cell Biochem. 2020;465(1–2):115–123. doi: 10.1007/s11010-019-03672-y
   PubMedGoogle Scholar
• Zhao J, Zhai B, Győrffy B, et al. Resveratrol reduces the stemness induced by platinum nanoparticles in breast cancer cells by affecting the PI3K/Akt/mTOR pathway. J Biol Inorg Chem. 2019;24(1):69–82.
   Google Scholar
• Yan X, Zhao N, Cai T. Resveratrol inhibits the proliferation of gastric cancer cells by blocking the Wnt/β-catenin pathway. Oncol Lett. 2019;18(5):4881–4887.
   Google Scholar
• Ke DYJ, El-Sahli S, Wang L, et al. The potential of natural products in the treatment of triple-negative breast cancer. Curr Cancer Drug Targets. 2022;22(5):388–03. doi: 10.2174/1568009622666211231140623
   PubMed Web of Science ®Google Scholar
• Costa RL, Han HS, Gradishar WJ, et al. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018;169:397–06. doi: 10.1007/s10549-018-4697-y
   PubMed Web of Science ®Google Scholar
• Sinha D, Sarkar N, Biswas J, et al. Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms. Semin Cancer Biol. 2016;40–41:209–32. doi: 10.1016/j.semcancer.2015.11.001
   PubMed Web of Science ®Google Scholar
• Alayev A, Berger SM, Kramer MY, et al. The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells. J Cell Biochem. 2015;116(3):450–7. doi: 10.1002/jcb.24997
   PubMed Web of Science ®Google Scholar
• Farghadani R, Naidu R. The anticancer mechanism of action of selected polyphenols in triple-negative breast cancer (TNBC). Biomed Pharmacother. 2023;165:115170. doi: 10.1016/j.biopha.2023.115170
   PubMed Web of Science ®Google Scholar
• Sunilkumar D, Drishya G, Chandrasekharan A, et al. Oxyresveratrol drives caspase-independent apoptosis-like cell death in MDA-MB-231 breast cancer cells through the induction of ROS. Biochem Pharmacol. 2020;173:113724. doi: 10.1016/j.bcp.2019.113724
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158. doi: 10.1126/science.aam7344
   PubMed Web of Science ®Google Scholar
• Gong L, Guo L, Zhang J, et al. Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis. Oncol Lett. 2019;17(3):2635–2642.
   Web of Science ®Google Scholar
• Deng Y, Li Y, Yang F, et al. Resveratrol prevents lipopolysaccharide-induced depressive-like behavior, microglial activation, oxidative stress, and neuroinflammation in mice. Brain Behav Immun. 2018;73:674–688.
   Google Scholar
• Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med. 2012;34(6):1217–1256. doi: 10.1016/j.mam.2013.01.006
   Web of Science ®Google Scholar
• Smith J, Miller AB, Jones LE, et al. Resveratrol downregulates CDK4 to G1 arrest in MDA-MB231 cells and induces apoptosis through caspase activation. Anticancer Agents Med Chem. 2020;20(5):544–554.
   Google Scholar
• Jones LE, Smith J, Yang X. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 preadipocytes. J Med Food. 2019;22(11):1137–1146.
   Google Scholar
• Chen C, Zhang D, Newman J, et al. Resveratrol enhances redox homeostasis and inhibits prostate cancer growth and metastasis by inhibiting the CDK4/6-cyclin D1 pathway. Cancer Lett. 2021;512:38–47. doi: 10.1016/j.canlet.2021.04.030
   PubMedGoogle Scholar
• Dillon PM, Petroni GR, Smolkin ME, et al. A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. J Immunother Cancer. 2017;5(1):1–0. doi: 10.1186/s40425-017-0295-5
   PubMedGoogle Scholar
• Ham SL, Nasrollahi S, Shah KN, et al. Phytochemicals potently inhibit migration of metastatic breast cancer cells. Integr Biol. 2015;7(7):792–800. doi: 10.1039/C5IB00121H
   Google Scholar
• Leon D, Uribe E, Zambrano A, et al. Implications of resveratrol on glucose uptake and metabolism. Molecules. 2017;22(3):398. doi: 10.3390/molecules22030398
   PubMed Web of Science ®Google Scholar
• Hung CM, Liu LC, Ho CT, et al. Pterostilbene enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistance triple negative breast cancer cells. J Agric Food Chem. 2017;65(51):11179–91. doi: 10.1021/acs.jafc.7b02358
   PubMed Web of Science ®Google Scholar
• Horgan XJ, Tatum H, Brannan E, et al. Resveratrol analogues surprisingly effective against triple‑negative breast cancer, independent of ERα. Oncol Rep. 2019;41(6):3517–26. doi: 10.3892/or.2019.7122
   PubMed Web of Science ®Google Scholar
• Lacerda‐Abreu MA, Russo‐Abrahão T, Meyer‐Fernandes JR. Resveratrol is an inhibitor of sodium‐dependent inorganic phosphate transport in triple‐negative MDA‐MB‐231 breast cancer cells. Cell Biol Int. 2021;45(8):1768–1775. doi: 10.1002/cbin.11616
   PubMed Web of Science ®Google Scholar
• Yar Saglam AS, Kayhan H, Alp E, et al. Resveratrol enhances the sensitivity of FL118 in triple-negative breast cancer cell lines via suppressing epithelial to mesenchymal transition. Mol Biol Rep. 2021;48(1):475–89. doi: 10.1007/s11033-020-06078-y
   PubMed Web of Science ®Google Scholar
• Huber R, Koval A, Marcourt L, et al. Chemoenzymatic synthesis of original stilbene dimers possessing wnt inhibition activity in triple-negative breast cancer cells using the enzymatic secretome of botrytis cinerea pers. Front Chem. 2022;10:881298. doi: 10.3389/fchem.2022.881298
   PubMed Web of Science ®Google Scholar
• Lucas J, Hsieh TC, Halicka HD, et al. Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling. Int J Oncol. 2018;53(4):1469–80. doi: 10.3892/ijo.2018.4512
   PubMed Web of Science ®Google Scholar
• Kala R, Shah HN, Martin SL, et al. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer. BMC Cancer. 2015;15(1):1–8. doi: 10.1186/s12885-015-1693-z
   PubMedGoogle Scholar
• Schlachterman A, Valle F, Wall KM, et al. Combined resveratrol, quercetin, and catechin treatment reduces breast tumor growth in a nude mouse model. Transl Oncol. 2008;1(1):19–27. doi: 10.1593/tlo.07100
   PubMed Web of Science ®Google Scholar
• Han X, Zhao N, Zhu W, et al. Resveratrol attenuates TNBC lung metastasis by down-regulating PD-1 expression on pulmonary T cells and converting macrophages to M1 phenotype in a murine tumor model. Cell Immunol. 2021;368:104423. doi: 10.1016/j.cellimm.2021.104423
   PubMed Web of Science ®Google Scholar
• Garvin S, Öllinger K, Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 2006;231(1):113–22. doi: 10.1016/j.canlet.2005.01.031
   PubMed Web of Science ®Google Scholar
• Liang ZJ, Wan Y, Zhu DD, et al. Resveratrol mediates the apoptosis of triple negative breast cancer cells by reducing POLD1 expression. Front Oncol. 2021;11:569295. doi: 10.3389/fonc.2021.569295
   PubMed Web of Science ®Google Scholar
• Yang MD, Sun Y, Zhou WJ, et al. Resveratrol enhances inhibition effects of cisplatin on cell migration and invasion and tumor growth in breast cancer MDA-MB-231 cell models in vivo and in vitro. Molecules. 2021;26(8):2204. doi: 10.3390/molecules26082204
   PubMed Web of Science ®Google Scholar
• Singh V, Verma S, Fatima F, et al. In silico study of a small bioactive molecule targeting topoisomerase II and P53-MDM2 complex in triple-negative breast cancer. ACS Omega. 2023;8(41):38025–37. doi: 10.1021/acsomega.3c03640
   PubMed Web of Science ®Google Scholar
• Singh AP, Singh R, Verma SS, et al. Health benefits of resveratrol: evidence from clinical studies. Med Res Rev. 2019;39(5):1851–91. doi: 10.1002/med.21565
   PubMed Web of Science ®Google Scholar
• Rushing BR, Wiggs A, Molina S, et al. Metabolomics analysis reveals novel targets of chemosensitizing polyphenols and omega-3 polyunsaturated fatty acids in triple negative breast cancer cells. Int J Mol Sci. 2023;24(5):4406. doi: 10.3390/ijms24054406
   PubMed Web of Science ®Google Scholar
• Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215(1):9–15. doi: 10.1111/j.1749-6632.2010.05842.x
   PubMed Web of Science ®Google Scholar
• Nivelle L, Hubert J, Courot E, et al. Anti-cancer activity of resveratrol and derivatives produced by grapevine cell suspensions in a 14 L stirred bioreactor. Molecules. 2017;22(3):474. doi: 10.3390/molecules22030474
   PubMed Web of Science ®Google Scholar
• Salla M, Pandya V, Bhullar KS, et al. Resveratrol and resveratrol-aspirin hybrid compounds as potent intestinal anti-inflammatory and anti-tumor drugs. Molecules. 2020;25(17):3849. doi: 10.3390/molecules25173849
   PubMed Web of Science ®Google Scholar
• Nawaz W, Zhou Z, Deng S, et al. Therapeutic versatility of resveratrol derivatives. Nutrients. 2017;9(11):1188. doi: 10.3390/nu9111188
   PubMed Web of Science ®Google Scholar
• Wang S, Willenberg I, Krohn M, et al. Growth-inhibiting activity of resveratrol imine analogs on tumor cells in vitro. PloS One. 2017;12(1):e0170502. doi: 10.1371/journal.pone.0170502
   PubMed Web of Science ®Google Scholar
• Morry J, Ngamcherdtrakul W, Gu S, et al. Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform. Mol Cancer Ther. 2017;16(4):763–72. doi: 10.1158/1535-7163.MCT-16-0644
   PubMed Web of Science ®Google Scholar
• Gambini J, Inglés M, Olaso G, et al. Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev. 2015;2015:1–13. doi: 10.1155/2015/837042
   Web of Science ®Google Scholar
• Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003;36(1):79–87. doi: 10.1016/S0009-9120(02)00397-1
   PubMed Web of Science ®Google Scholar
• Walle T, Hsieh F, DeLegge MH, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32(12):1377–82. doi: 10.1124/dmd.104.000885
   PubMed Web of Science ®Google Scholar
• Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1246–1252. doi: 10.1158/1055-9965.EPI-07-0022
   PubMed Web of Science ®Google Scholar
• Almeida L, Vaz‐da‐Silva M, Falcão A, et al. Pharmacokinetic and safety profile of trans‐resveratrol in a rising multiple‐dose study in healthy volunteers. Mol Nutr Food Res. 2009;53(S1):S7–15. doi: 10.1002/mnfr.200800177
   PubMed Web of Science ®Google Scholar
• He L, Gu J, Lim LY, et al. Nanomedicine-mediated therapies to target breast cancer stem cells. Front Pharmacol. 2016;7:313. doi: 10.3389/fphar.2016.00313
   PubMed Web of Science ®Google Scholar
• Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomed. 2012;7(4):597–615. doi: 10.2217/nnm.12.22
   PubMed Web of Science ®Google Scholar
• Sharifi-Rad J, Quispe C, Mukazhanova Z, et al. Resveratrol-based nanoformulations as an emerging therapeutic strategy for cancer. Front Mol Biosci. 2021;8:649395. doi: 10.3389/fmolb.2021.649395
   PubMed Web of Science ®Google Scholar
• Shindikar A, Singh A, Nobre M, et al. Curcumin and resveratrol as promising natural remedies with nanomedicine approach for the effective treatment of triple negative breast cancer. J Oncol. 2016;2016:1–13. doi: 10.1155/2016/9750785
   Web of Science ®Google Scholar
• Yotsumoto K, Ishii K, Kokubo M, et al. Improvement of the skin penetration of hydrophobic drugs by polymeric micelles. Int J Pharm. 2018;553(1–2):132–40. doi: 10.1016/j.ijpharm.2018.10.039
   PubMed Web of Science ®Google Scholar
• Guo X, Zhao Z, Chen D, et al. Co-delivery of resveratrol and docetaxel via polymeric micelles to improve the treatment of drug-resistant tumors. Asian J Pharm Sci. 2019;14(1):78–85. doi: 10.1016/j.ajps.2018.03.002
   PubMed Web of Science ®Google Scholar
• Vieira DB, Gamarra LF. Advances in the use of nanocarriers for cancer diagnosis and treatment. Einstein (Sao Paulo). 2016;14(1):99–103. doi: 10.1590/S1679-45082016RB3475
   PubMedGoogle Scholar
• Zu Y, Overby H, Ren G, et al. Resveratrol liposomes and lipid nanocarriers: comparison of characteristics and inducing browning of white adipocytes. Colloids Surf B. 2018;164:414–23. doi: 10.1016/j.colsurfb.2017.12.044
   PubMed Web of Science ®Google Scholar
• Ahmad MZ, Alkahtani SA, Akhter S, et al. Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art. J Drug Target. 2016;24(4):273–93. doi: 10.3109/1061186X.2015.1055570
   PubMed Web of Science ®Google Scholar
• Talluri SV, Kuppusamy G, Karri VV, et al. Lipid-based nanocarriers for breast cancer treatment–comprehensive review. Drug Delivery. 2016;23(4):1291–1305. doi: 10.3109/10717544.2015.1092183
   PubMed Web of Science ®Google Scholar
• Chowdhury N, Vhora I, Patel K, et al. Development of hot melt extruded solid dispersion of tamoxifen citrate and resveratrol for synergistic effects on breast cancer cells. AAPS Pharm Sci Tech. 2018;19(7):3287–97. doi: 10.1208/s12249-018-1111-3
   PubMed Web of Science ®Google Scholar
• Malhotra A, Bath S, Elbarbry F. An organ system approach to explore the antioxidative, anti-inflammatory, and cytoprotective actions of resveratrol. Oxid Med Cell Longev. 2015;2015:1–15. doi: 10.1155/2015/803971
   Web of Science ®Google Scholar
• Dyck GJ, Raj P, Zieroth S, et al. The effects of resveratrol in patients with cardiovascular disease and heart failure: a narrative review. Int J Mol Sci. 2019;20(4):904. doi: 10.3390/ijms20040904
   PubMed Web of Science ®Google Scholar
• Fan C, Kong F, Shetti D, et al. Resveratrol loaded oxidized mesoporous carbon nanoparticles: a promising tool to treat triple negative breast cancer. Biochem Biophys Res Commun. 2019;519(2):378–84. doi: 10.1016/j.bbrc.2019.09.016
   PubMed Web of Science ®Google Scholar
• Al-Jubori AA, Sulaiman GM, Tawfeeq AT, et al. Layer-by-layer nanoparticles of tamoxifen and resveratrol for dual drug delivery system and potential triple-negative breast cancer treatment. Pharmaceutics. 2021;13(7):1098. doi: 10.3390/pharmaceutics13071098
   PubMed Web of Science ®Google Scholar
• Gregoriou Y, Gregoriou G, Yilmaz V, et al. Resveratrol loaded polymeric micelles for theranostic targeting of breast cancer cells. Nanotheranostics. 2021;5(1):113. doi: 10.7150/ntno.51955
   PubMedGoogle Scholar
• Wróblewska A, Szczygieł A, Szermer-Olearnik B, et al. Macrophages as promising carriers for nanoparticle delivery in anticancer therapy. Int J Nanomedicine. 2023;18:4521–39. doi: 10.2147/IJN.S421173
   PubMed Web of Science ®Google Scholar
• Qiu Y, Ren K, Zhao W, et al. A “dual-guide” bioinspired drug delivery strategy of a macrophage-based carrier against postoperative triple-negative breast cancer recurrence. J Control Release. 2021;329:191–204. doi: 10.1016/j.jconrel.2020.11.039
   PubMed Web of Science ®Google Scholar
• Ren K, Qiu Y, Yu Q, et al. Macrophage-mediated multi-mode drug release system for photothermal combined with anti-inflammatory therapy against postoperative recurrence of triple negative breast cancer. Int J Pharm. 2021;607:120975. doi: 10.1016/j.ijpharm.2021.120975
   PubMedGoogle Scholar
• Shin GR, Kim HE, Ju HJ, et al. Injectable click-crosslinked hydrogel containing resveratrol to improve the therapeutic effect in triple negative breast cancer. Mater Today Bio. 2022;16:100386. doi: 10.1016/j.mtbio.2022.100386
   PubMedGoogle Scholar
• Liu X, Liu J, Xu S, et al. Gold nanoparticles functionalized with au–se-Bonded peptides used as gatekeepers for the off-target release of resveratrol in the treatment of triple-negative breast cancer. ACS Appl Mater Interfaces. 2023;15(2):2529–37. doi: 10.1021/acsami.2c10221
   PubMed Web of Science ®Google Scholar
• Bozorgi A, Haghighi Z, Khazaei MR, et al. The anti‐cancer effect of chitosan/resveratrol polymeric nanocomplex against triple‐negative breast cancer; an in vitro assessment. IET Nanobiotechnol. 2023;17(2):91–102. doi: 10.1049/nbt2.12108
   PubMed Web of Science ®Google Scholar